{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:00:54Z","timestamp":1763348454282,"version":"3.43.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>Our study aims to report the prevalence of potentially actionable oncogenic variants in a sample of pediatric tumors from a single institution using a reference laboratory for tumor profiling. We investigated genomic alterations and immunotherapy biomarkers such a tumor mutation burden, microsatellite instability, and programmed death-ligand 1. Patients treated in the Cook Children\u2019s Health Care System who had tumor profiling performed by Foundation Medicine between January 1, 2013, and May 1, 2019, were included. Demographic variables, results of tumor profiling, and subsequent use of targeted therapies were captured. Eighty-one patients were in our final data set; patients had diagnoses of central nervous system tumors (n=5), leukemia and lymphoma (n=4), neuroblastoma (n=32), and other solid tumors (n=40). One or more genomic alterations were identified in 68 (84%) of patients, 34 of which had potential targeted therapies available. In all, 44\/51 patients tested for tumor mutation burden had low tumor burden, and the rest had intermediate burden. All 41 patients tested for microsatellite instability status were microsatellite stable. Six of 34 patients tested for programmed death-ligand 1 status were positive. Twelve patients received targeted therapy. This study highlights a subset of pediatric tumors harboring targetable genetic alterations and describes the use of a reference laboratory for tumor profiling.<\/jats:p>","DOI":"10.1097\/mph.0000000000002485","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T16:00:10Z","timestamp":1652198410000},"page":"63-69","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Lessons Learned: Utilization of a Reference Laboratory for Targeted Sequencing of Pediatric Tumors at a Single Institution"],"prefix":"10.1097","volume":"45","author":[{"given":"Aubrey","family":"Swilling","sequence":"first","affiliation":[{"name":"University of North Texas Health Science Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Pham","sequence":"additional","affiliation":[{"name":"University of North Texas Health Science Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Wang","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Vallance","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler","family":"Hamby","sequence":"additional","affiliation":[{"name":"Research Operations, Cook Children\u2019s Medical Center, Fort Worth, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anish","family":"Ray","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMsr1804754","article-title":"The major causes of death in children and adolescents in the United States","volume":"379","author":"Cunningham","year":"2018","journal-title":"N Engl J Med"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"R3-20250804","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R4-20250804","first-page":"305","article-title":"The current state of molecular testing in the treatment of patients with solid tumors, 2019","volume":"69","author":"El-Deiry","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/cpt.785","article-title":"Development of molecularly targeted therapies to treat pediatric malignancies","volume":"102","author":"Stewart","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers [published correction appears in Nature. 2018;559:E10]","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study [published correction appears in Lancet Oncol. 2018;19:e229]","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14737140.2019.1538796","article-title":"Larotrectinib for the treatment of TRK fusion solid tumors","volume":"19","author":"Laetsch","year":"2019","journal-title":"Expert Rev Anticancer Ther"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/pbc.26056","article-title":"The role of leukapheresis in the current management of hyperleukocytosis in newly diagnosed childhood acute lymphoblastic leukemia [published correction appears in Pediatr Blood Cancer. 2017;64]","volume":"63","author":"Nguyen","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jamaoncol.2015.5699","article-title":"Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors","volume":"2","author":"Parsons","year":"2016","journal-title":"JAMA Oncol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamaoncol.2015.5689","article-title":"Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the Individualized Cancer Therapy (iCat) Study","volume":"2","author":"Harris","year":"2016","journal-title":"JAMA Oncol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2016.06.009","article-title":"Next-generation personalised medicine for high-risk paediatric cancer patients\u2014The INFORM pilot study","volume":"65","author":"Worst","year":"2016","journal-title":"Eur J Cancer"},{"key":"R16-20250804","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26365","article-title":"Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors","author":"Pincez","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20250804","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26288","article-title":"Precision medicine in pediatric oncology: lessons learned and next steps","author":"Mody","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13073-016-0389-6","article-title":"Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations","volume":"8","author":"Oberg","year":"2016","journal-title":"Genome Med"},{"key":"R19-20250804","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26258","article-title":"A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials","author":"Dorris","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1634\/theoncologist.2019-0615","article-title":"A systematic review of pediatric phase I trials in oncology: toxicity and outcomes in the era of targeted therapies","volume":"25","author":"Cohen","year":"2020","journal-title":"Oncologist"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAI.0000000000000575","article-title":"Microsatellite instability: a predictive biomarker for cancer immunotherapy","volume":"26","author":"Chang","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/1078-0432.CCR-14-1100","article-title":"Anaplastic lymphoma kinase as a cancer target in pediatric malignancies","volume":"22","author":"Moss\u00e9","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer [published correction appears in N Engl J Med. 2011;364:588]","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/cas.13333","article-title":"The role of anaplastic lymphoma kinase in pediatric cancers","volume":"108","author":"Takita","year":"2017","journal-title":"Cancer Sci"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11523-017-0528-z","article-title":"Targeting anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma (RMS) with the second-generation ALK inhibitor ceritinib","volume":"12","author":"van Erp","year":"2017","journal-title":"Target Oncol"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"1.30.1","DOI":"10.1002\/cpbi.5","article-title":"The GeneCards Suite: from gene data mining to disease genome sequence analyses","volume":"54","author":"Stelzer","year":"2016","journal-title":"Curr Protoc Bioinformatics"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:08:10Z","timestamp":1754338090000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002485","relation":{},"ISSN":["1077-4114"],"issn-type":[{"type":"print","value":"1077-4114"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"2021-09-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}